
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Supplementation with antioxidants and folinic acid has no impact on the psychomotor and language development of children with Down syndrome, according to a study published Feb. 21 in BMJ.






